Dr. Juan Manuel Sepúlveda Sánchez

Nº total: 114

Publicaciones más destacadas:

1. Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas. Pérez-García VM, Ayala-Hernández LE, Belmonte-Beitia J, Schucht P, Murek M, Raabe A, Sepúlveda J. PLoS Comput Biol. 2019 Jul 15;15(7):e1006778. doi: 10.1371/journal.pcbi.1006778. eCollection 2019 Jul. PMID: 31306418
2. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. Ciruelos E, Apellániz-Ruiz M, Cantos B, Martinez-Jáñez N, Bueno-Muiño C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepúlveda JM. Oncologist. 2019 Apr 25.
3. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A. Clin Transl Oncol. 2019 Mar 15. doi: 10.1007/s12094-019-02070-6.
4. Dacomitinib: an investigational drug for the treatment of glioblastoma. Sepúlveda JM, Sánchez-Gómez P, Vaz Salgado MÁ, Gargini R, Balañá C. Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225. Epub 2018 Oct 5.
5. SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Sepúlveda-Sánchez JM, Muñoz Langa J, Arráez MÁ, Fuster J, Hernández Laín A, Reynés G, Rodríguez González V, Vicente E, Vidal Denis M, Gallego Ó. Clin Transl Oncol. 2018 Jan;20(1):3-15. doi: 10.1007/s12094-017-1790-3
6. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Neuro Oncol. 2017 Oct 19;19(11):1522-1531.
7. Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study. Sepúlveda-Sánchez JM, Conde-Moreno A, Barón M, Pardo J, Reynes G and Belenguer A. Oncology Letters 2017. Jun;13(6):4093-4100.
8. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M, Mendez-Vidal MJ, Pinto A, Sastre J, de Prado DS, Terrasa J, Vázquez S, Powles T, Beyer J, Castellano D, Del Muro XG; Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group. Eur Urol Focus. 2017 Apr;3(2-3):280-286.
9. Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendrolgioma. Hernández-Lain A, Hilario A, Sepúlveda JM, Cantero D, Ramos A, Pérez-Núñez A. Neurology 2016 Jul 5;87(1):114-5.
10. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. J Neurooncol. 2016 May;127(3):569-79.
11. GEINOFOTE: Efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Pérez-Segura P, Manneh R, Ceballos I, García A, Benabides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J. Clinical and Translational oncology 2016 Aug;18(8):805-12.
12. Brain perfusión and permeability in patients with advanced, refractory glioblastoma treated with Lomustine and the transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate. Sepúlveda-Sánchez J, Ramos A, De Velasco G, Castellano D, García de la Torre M, Rodón J, Lahn MF. Oncol Lett 2015 Jun;9(6):2442-2448.
13. Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as therapeutic target. Zahonero C, Sepúlveda JM, Sánchez-Gómez P. Rev Neurol 2015 Jul 16;61(2):85-93
14. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Segura P, Berrocal A, Reynes G, Gallego O, Capellades J Ordoñez JM, La Orden B, Balañá C. Clinical and Translational Oncology 2015 Sep;17(9):743-50. PMID: 26033428
15. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Zahonero C, Aguilera P, Ramírez-Castillejo C, Pajares M, Bolos MV, Cantero D, Perez-Nuñez A, Hernández-Laín A, Sánchez-Gómez P, Sepúlveda JM. Mol Cancer Ther. 2015 Jul;14(7):1548-58.
16. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-? receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Rodón J, Carducci MA, Sepúlveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desaiah D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, Baselga J. Invest New Drugs 2015 Apr;33(2):357-70.
17. First-in-human Dose Study of the novel Transforming Growth Factor-? Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Rodón J, Carducci MA, Sepúlveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desaiah D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, Baselga J. Clin Cancer Res. 2015 Feb 1;21(3):553-60.
18. A Prognostic Model Based on Preoperative MRI Predicts Overall Survival in Patients with Diffuse Gliomas. Hilario A, Sepulveda JM, Perez-Nuñez A, Salvador E, Millan JM, Hernandez-Lain A, Rodriguez-Gonzalez V, Lagares A, Ramos A. AJNR Am J Neuroradiol. 2014 Jan 23.
19. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A, Sepúlveda JM, Sánchez-Gómez P. J Clin Invest. 2013 Jun 3;123(6):2475-87.
20. Prognostic implications of clinical, radiologic, and pathologic features in patients with oligodendroglial tumors after long-term follow-up. Sepúlveda JM, Martínez JC, Díez-Lobato R, Hernández-Laín A, González P, Ramos A, Ricoy JR. Clinical Neuropathology 2009;28(1):11-20.